The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University , Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S. , the incidence of babesiosis has been increasing;
WASHINGTON , July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label, expanded
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston . Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular cure as determined
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. 60 Degrees Pharmaceuticals recently announced it has entered into an agreement
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans The study will be the world’s first clinical trial to evaluate tafenoquine in human
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptoms Planned study at North Carolina State College
Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand . Gross profit increased from ( $55.9 thousand ) to $51.0 thousand . WASHINGTON , May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company
The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study to date.
Trial planning and execution to proceed as planned WASHINGTON , May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that the U.S.
Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is expensive WASHINGTON , April 03, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (or the “Company”),
